{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:28Z","timestamp":1786982848449,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer Italia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Growth hormone deficiency (GHD) is a rare condition with a worldwide prevalence of 1 patient in 4000 to 10,000 live births, placing a significant economic burden on healthcare systems. The aim of this study is to generate evidence on the economic burden of children and adolescents with GHD treated with rhGH and their parents in Italy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cost of illness analysis, adopting the prevalence approach, has been developed, producing evidence on the total annual cost sustained by the Italian National Health System (NHS) and by the society. The study is based on original data collected from a survey conducted among Italian children and adolescents with GHD and their parents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>143 children\/adolescents with GHD and their parents participated to the survey, conducted from May to October 2021. Patients had a mean age of 12.2 years (SD: 3.1) and were mostly males (68.5%).<\/jats:p>\n                    <jats:p>The average direct healthcare cost sustained by the NHS was \u20ac 8,497.2 per patient\/year; adding the out-of-pocket expenses (co-payments and expenses for private healthcare service), the total expense was \u20ac 8,568.6. The indirect costs, assessed with the human capital approach, were \u20ac 847.9 per patient\/year. The total of direct and indirect cost is \u20ac 9,345.1 from the NHS perspective, and \u20ac 9,416.5 from a social perspective. The total cost incurred by the Italian NHS for children with GHD (range: 5,708\u20138,354) was estimated in \u20ac 48.5\u201371.0 million, corresponding to 0.04\u20130.06% of the total Italian public health expense in the year 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The total annual cost for GHD children is close to \u20ac 10,000, and is mainly due to the cost of rhGH treatment. This cost is almost entirely sustained by the NHS, with negligible out-of-pocket expenses.<\/jats:p>\n                    <jats:p>The economic burden on the Italian NHS for the health care of established GHD children is fourfold higher than the prevalence of the disease in the overall Italian population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-023-02277-z","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T01:02:36Z","timestamp":1704848556000},"page":"1743-1750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The economic burden of pediatric growth hormone deficiency in Italy: a cost of illness study"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-7519","authenticated-orcid":false,"given":"M.","family":"Cappa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pozzobon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0200-1202","authenticated-orcid":false,"given":"M.","family":"Orso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7183-5238","authenticated-orcid":false,"given":"M.","family":"Maghnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6217-1919","authenticated-orcid":false,"given":"G.","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-2850","authenticated-orcid":false,"given":"F.","family":"Spandonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Granato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1310-3300","authenticated-orcid":false,"given":"M.","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-0223","authenticated-orcid":false,"given":"B.","family":"Polistena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"issue":"10","key":"2277_CR1","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41574-021-00539-5","volume":"17","author":"C Hage","year":"2021","unstructured":"Hage C, Gan HW, Ibba A, Patti G, Dattani M, Loche S et al (2021) Advances in differential diagnosis and management of growth hormone deficiency in children. Nat Rev Endocrinol 17(10):608\u2013624","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2277_CR2","first-page":"1","volume":"38","author":"L Audi","year":"2013","unstructured":"Audi L, Fernandez-Cancio M, Camats N, Carrascosa A (2013) Growth hormone deficiency: an update. Minerva Endocrinol 38(1):1\u201316","journal-title":"Minerva Endocrinol"},{"issue":"6","key":"2277_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000452150","volume":"86","author":"A Grimberg","year":"2016","unstructured":"Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB et al (2016) Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 86(6):361\u2013397","journal-title":"Horm Res Paediatr"},{"key":"2277_CR4","unstructured":"Agenzia Italiana del Farmaco (2004) DETERMINAZIONE 29 ottobre 2004 Note AIFA 2004 (Revisione delle note CUF). (GU Serie Generale n.259 del 04-11-2004\u2014Suppl. Ordinario n. 162). www.gazzettaufficiale.it\/eli\/id\/2004\/11\/04\/04A10760\/sg. Accessed 02 Mar, 2022"},{"key":"2277_CR5","unstructured":"Agenzia Italiana del Farmaco (2021) Determina 6 aprile 2021. Modifica della Nota AIFA 39 di cui alla determina AIFA n. 458\/2020. (Determina n. DG 390\/2021). (21A02189) (GU Serie Generale n.87 del 12-04-2021). www.gazzettaufficiale.it\/eli\/id\/2021\/04\/12\/21A02189\/sg. Accessed 02 Mar, 2022"},{"issue":"5","key":"2277_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/BF03344127","volume":"29","author":"G Migliaretti","year":"2006","unstructured":"Migliaretti G, Aimaretti G, Borraccino A, Bellone J, Vannelli S, Angeli A et al (2006) Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002\u20132004: data from the GH registry. J Endocrinol Invest 29(5):438\u2013442","journal-title":"J Endocrinol Invest"},{"key":"2277_CR7","unstructured":"Pricci F, Agazio E, Villa M (Ed.) (2021) Trattamento con l\u2019ormone somatotropo in Italia al 2020: rapporto annuale del Registro Nazionale degli Assuntori dell\u2019Ormone della Crescita. Roma: Istituto Superiore di Sanit\u00e0 (Rapporti ISTISAN 21\/26)"},{"issue":"2","key":"2277_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264403","volume":"17","author":"M Orso","year":"2022","unstructured":"Orso M, Polistena B, Granato S, Novelli G, Di Virgilio R, La Torre D et al (2022) Pediatric growth hormone treatment in Italy: a systematic review of epidemiology, quality of life, treatment adherence, and economic impact. PLoS ONE 17(2):e0264403","journal-title":"PLoS ONE"},{"issue":"12","key":"2277_CR9","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s40618-023-02106-3","volume":"46","author":"M Maghnie","year":"2023","unstructured":"Maghnie M, Orso M, Polistena B, Cappa M, Pozzobon G, d'Angela D et al (2023) Quality of life in children and adolescents with growth hormone deficiency and their caregivers: an Italian survey. J Endocrinol Invest 46(12):2513\u20132523","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2277_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C et al (2022) Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health 25(1):3\u20139","journal-title":"Value Health"},{"issue":"1","key":"2277_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C et al (2022) Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health 25(1):10\u201331","journal-title":"Value Health"},{"key":"2277_CR12","unstructured":"Ministero della Salute (2012) Decreto 18 ottobre 2012, pubblicato nella Gazzetta Ufficiale n. 23 del 28 gennaio 2013. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. (13A00528). https:\/\/www.trovanorme.salute.gov.it\/norme\/dettaglioAtto?id=45074&completo=true. Accessed 26 Feb, 2022"},{"key":"2277_CR13","doi-asserted-by":"crossref","unstructured":"Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E, et al (2010) Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess 14(42):1\u2013209 (iii\u2013iv)","DOI":"10.3310\/hta14420"},{"issue":"10","key":"2277_CR14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40618-014-0138-x","volume":"37","author":"F Spandonaro","year":"2014","unstructured":"Spandonaro F, Cappa M, Castello R, Chiarelli F, Ghigo E, Mancusi L (2014) The impact of real practice inappropriateness and devices\u2019 inefficiency to variability in growth hormone consumption. J Endocrinol Invest 37(10):979\u2013990","journal-title":"J Endocrinol Invest"},{"key":"2277_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2147\/CEOR.S195265","volume":"11","author":"J Foo","year":"2019","unstructured":"Foo J, Maghnie M, Colao A, Vlachaki I, Colombo G (2019) Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy. ClinicoEcon Outcomes Res 11:525\u2013537","journal-title":"ClinicoEcon Outcomes Res"},{"issue":"5","key":"2277_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/BF03347461","volume":"34","author":"S Pagani","year":"2011","unstructured":"Pagani S, Meazza C, Laarej K, Cantoni F, Bozzola M (2011) Efficacy of long-term growth hormone therapy in short children with reduced growth hormone biological activity. J Endocrinol Invest 34(5):366\u2013369","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"2277_CR17","first-page":"1118","volume":"27","author":"P Kaplowitz","year":"2021","unstructured":"Kaplowitz P, Manjelievskaia J, Lopez-Gonzalez L, Morrow CD, Pitukcheewanont P, Smith A (2021) Economic burden of growth hormone deficiency in a US pediatric population. J Manag Care Spec Pharm 27(8):1118\u20131128","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02277-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02277-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02277-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T07:13:50Z","timestamp":1719213230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02277-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["2277"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02277-z","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"22 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Simona Granato, Giuseppe Novelli and Daria La Torre are employees of Pfizer; they contributed in writing and reviewing the manuscript. Mohamad Maghnie has received research support from Merck Serono, and Pfizer; has consulted for BioMarin, Merck Serono, Novo Nordisk, Pfizer, and Sandoz. Barbara Polistena declares to have received in the last 5 years payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Eli Lilly, Janssen Cilag, Nestle\u00b4 HS, Novartis, Novo Nordisk, Pfizer, Servier, Takeda, Teva; in addition, she received consulting fees from UCB. Marco Cappa declares to have received research support from Merck-Serono, Pfizer, Novo\u00a0Nordisk; has consulted for AMYRTH, Pfizer, Novo Nordisk, Merck-Serono. Giuseppa Patti has received research support from Merck Serono and has consulted for Merck Serono, Novo Nordisk, Pfizer, and Sandoz. Federico Spandonaro declares to have received in the last 5 years payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the following commercial sources: Allergan, Amgen, Astellas, Baxter, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Janssen Cilag, Jazzpharma, Mylan, Nestle\u00b4 HS, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Servier, Shire, Takeda, Teva; in addition, he received consulting fees from Amgen. Mariacarolina Salerno has received research support from Merck Serono and has consulted for Merck Serono, Novo Nordisk, Pfizer, and Sandoz. All other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"A signed informed consent was not required from participants in this anonymous and voluntary questionnaire survey.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}